Clinical Trials

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06843447 2026-05-26

MK-5909-003

Phase 1/2 Recruiting

460 enrolled

Ovarian Cancer Recurrent

NCT07111546 2026-05-26

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

140 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT07214779 2026-05-26

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT05139017 2026-05-22

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06312137 2026-05-22

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06545955 2026-05-22

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06841354 2026-05-22

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07604766 2026-05-22

RAINFOL-02

82 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07280377 2026-05-19

GOBLET

122 enrolled

Anal Cancer Metastatic

NCT05173142 2026-05-15

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

Phase 1/2 Completed

190 enrolled

Stomach Neoplasms

NCT06623422 2026-05-15

INTerpath-009

680 enrolled

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04589234 2026-05-14

Saltikva for Metastatic Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT05548296 2026-05-14

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

401 enrolled

Endometrial Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

620 enrolled

CNSGastrointestinalGynecologic

Biliary Tract Neoplasms

NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

Phase 1 Recruiting

272 enrolled

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07491445 2026-05-14

RASolute 303

900 enrolled

Phase 2 Active not recruiting

Pancreatic Neoplasms

NCT04274426 2026-05-13

MIROVA

136 enrolled

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Phase 2 Completed

194 enrolled 16 charts

Phase 2 Not yet recruiting

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT07578337 2026-05-13

NUMANTIA-2

40 enrolled

Neoplasms, Pancreatic Neoplasms

NCT02453282 2026-05-12

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03819465 2026-05-12

MAGELLAN

175 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07106762 2026-05-12

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

Urinary Bladder Neoplasms

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07566156 2026-05-11

EV-309

390 enrolled

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT04658862 2026-05-08

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

295 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06081959 2026-05-08

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06211764 2026-05-08

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-05-08

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06608927 2026-05-08

PRISM-1

610 enrolled

Pancreatic Neoplasms

NCT06919965 2026-05-08

MoonRISe-3

220 enrolled